Navigation Links
Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
Date:6/22/2008

Efficacy and safety data were generally consistent with oral olanzapine

with the exception of injection-related events

VENICE, Italy, June 23 /PRNewswire-FirstCall/ -- Results from olanzapine long-acting injection (LAI) clinical trials showed that the efficacy and safety profile of olanzapine LAI was generally consistent with that of Zyprexa(R) (olanzapine) with the exception of injection-related events. Results from a 24-week maintenance study (HGKA) and interim findings from an ongoing open-label study (HGKB) were presented at the first annual Schizophrenia International Research Society (SIRS) Conference in Venice, Italy.

Olanzapine LAI is an investigational formulation that combines olanzapine with a pamoate salt, resulting in an extended delivery of up to four weeks. Since olanzapine was introduced in 1996, it has been prescribed to approximately 24 million people worldwide.

"These studies offer insight into the potential of olanzapine LAI as a maintenance treatment for patients with schizophrenia who may have difficulty taking medication on a daily basis," said David McDonnell, M.D., clinical research physician at Lilly. "Schizophrenia is a challenging and complex disease to manage, which is why finding new ways to support patient compliance with medication is so important."

Regulatory reviews of olanzapine LAI applications are ongoing in the European Union, Canada, Australia and United States.

Notes for editors:

About HGKA (24-week maintenance of effect study)

In this 24-week double-blind maintenance study, a total of 1,065 adult outpatients with schizophrenia who had been stabilized previously on open-label oral olanzapine (10, 15, or 20 mg daily) for four to eight weeks were randomized to one of three therapeutic dosing regimens of olanzapine LAI (150 mg every two weeks, 405 mg every four weeks, or 300 mg every two weeks), or to a low reference dose of olanzapine LAI (45 mg every four we
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
2. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
3. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
4. New Diabetes Compound AVE0010 Showed Clear Dose Response Results With Once-A-Day Injection in Phase IIb Study
5. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
6. Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma
7. VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
8. New Eloxatin(R) (oxaliplatin injection) Prescribing Information in the U.S. Includes Six-Year Overall Survival Data
9. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
10. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
11. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
(Date:7/11/2014)... July 11, 2014 Patient engagement has ... consequently, organizations are turning to an assortment of ... As part of this evolving approach to patient ... communicate and engage patients throughout their experiences with ... empowerment. By mapping the patient journey and employing ...
(Date:7/11/2014)... N.C. , July 11, 2014 ... approaches are evolving across industry sectors to better ... examining better ways to engage with and understand ... inform themselves and make critical purchasing decisions. ... firm, Best Practices, LLC, one area where organizations ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
... SAN DIEGO, Aug. 26 CareFusion (NYSE: ... announced the national commercial launch of the AVA max® ... during kyphoplasty, a procedure for treating spinal compression fractures. ... represents a competitive breakthrough and is expected to enhance ...
... Inc. (Nasdaq: ALXA ) announced today that ... to Cypress Bioscience, Inc. (Nasdaq: CYPB).  The Staccato ... system designed to help people stop smoking.  The ... a well-validated smoking cessation approach by delivering nicotine via ...
Cached Medicine Technology:CareFusion Announces National Launch of Spinal Fracture Device 2CareFusion Announces National Launch of Spinal Fracture Device 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 2Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 3Alexza's Staccato® Nicotine Licensed to Cypress Bioscience 4
(Date:7/11/2014)... 11, 2014 Ticket Down reports that tickets ... and 3rd place World Cup Match between Brazil and ... will take place on Saturday, July 12th at Estadio Nacional ... Finals will take place on Sunday, July 13th at Estadio ... All tickets for the 2014 World Cup are guaranteed to ...
(Date:7/11/2014)... York (PRWEB) July 11, 2014 ... , filed against Johnson & Johnson’s Ethicon Inc. ... Liebhard LLP notes that the Texas Attorney General’s ... company’s marketing of surgical mesh products used to ... According to a report from kens5.com, the probe ...
(Date:7/11/2014)... July 11, 2014 Butler Mobility has recently ... Inclined Platform Lifts . Previously the two standard colors ... new beautiful earth tone colors as standard colors at no ... in the home but will enhance the beauty of the ... any home color scheme or individual décor. , The new ...
(Date:7/11/2014)... (HealthDay News) -- Reducing the number of deer in ... disease and other tick-borne infections among people, new research ... be manipulated to reduce human interactions with deer, infected ... the researchers wrote. White-tailed deer are the primary ... to people. The study included nearly all the ...
(Date:7/11/2014)... -- People with the lowest incomes may have a higher ... a new study suggests. People with PAD have narrowing ... often the legs. The condition causes leg pain and is ... body. People with PAD have a higher risk for heart ... people with PAD who took part in the U.S. National ...
Breaking Medicine News(10 mins):Health News:Argentina vs. Germany World Cup Finals Tickets & Brazil vs. Netherlands 3rd Place World Cup Tickets Are in Huge Demand 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 2Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 3Health News:Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Report of Texas Probe into Ethicon Pelvic Mesh Marketing 4Health News:Butler Mobility Products Announces Five New Standard Colors for Their Inclined Platform Lifts 2Health News:Poor More Prone to Leg Circulation Trouble 2
... Young adults whose mothers experienced psychological trauma during ... Irvine-led study found. The researchers discovered that this ... regions that control cell aging processes. The study results, ... of the National Academy of Sciences , point to ...
... 11th leading cause of death in the United States. Every ... Sadly, each year tens of thousands die by suicide. While ... warning signs exist. Often a simple question from a family ... and treatment. A new review in the August ...
... CHAPEL HILL, N.C. - Joanne M. Jordan, MD, MPH, director ... North Carolina at Chapel Hill, has received the 2011 Distinguished ... (RSS). The purpose of the award is to recognize ... enhancement of rural life and rural people. For more than ...
... cell phones have led to preventive policies in France, Israel, ... the health risks associated with exposure to the radiation energy ... of the Environmental Health Trust, in a timely and informative ... by Mary Ann Liebert, Inc. The interview is available free ...
... HealthDay Reporter , MONDAY, Aug. 1 (HealthDay News) -- ... acid DHA during pregnancy, their babies have fewer cold symptoms ... and 3 months of age, about 38 percent of babies ... symptoms, compared to about 45 percent of the babies whose ...
... , MONDAY, Aug. 1 (HealthDay News) -- Despite the ... -- which can be done at home or in day ... However, colon cleansing can cause serious side effects ranging ... the report say. Colon cleansing -- also called colonic ...
Cached Medicine News:Health News:UCI-led study links prenatal exposure to stress with accelerated cell aging 2Health News:Mayo Clinic: Primary physicians may hold key to suicide prevention 2Health News:Dr. Joanne Jordan receives Distinguished Service to Rural Life Award 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 2Health News:Prenatal Omega-3 Fatty Acid Supplements May Cut Babies' Colds 3Health News:Colon Cleansing Has No Health Benefit, May Harm: Report 2
... grafting or creation of a vascular access, ... is of the utmost importance in many ... for those seeking a high-precision tunneling instrument. ... risk of twisting or kinking for more ...
... have met the challenges of the ... exceptional performance and quality, they have ... worldwide. These grafts require no preclotting, ... infection, and ensure utmost thrombectomy safety. ...
... the challenges of the most demanding vascular ... exceptional performance and quality, they have earned ... grafts require no preclotting, resist dilatation and ... thrombectomy safety. Gore vascular grafts are also ...
... the newest vascular graft offering from W. ... vascular surgical products for more than two ... and compression problems that can lead ... all of the benefits of a ring ...
Medicine Products: